ESR1 and neoplasm: Data from this study confirmed ERLIN2 as a direct target, with overexpression of miR-410 shown to downregulate migration, proliferation, and invasion of estrogen receptor (ER)-positive cells in vitro and to attenuate tumor growth in vivo [40].